Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
Provided is a method for reducing viral load of porcine circovirus type 2 (PCV-2) in a pig by inducing an immune response against PCV-2 through the administration of an immunogenic composition comprising a PCV-2 antigen. A preferred antigen is a vector containing a PCV-2 nucleotide sequence. In a particularly preferred embodiment, the PCV-2 nucleotide sequence is ORF4, ORF13, or ORF4 and ORF13. In some embodiments, the immunogenic composition includes one or more additional pig pathogens.
1. A method for reducing viral load of porcine circovirus-2 (PCV-2) in a pig comprising inducing an immunological or immunogenic response against PCV-2 in the pig comprising administering to the pig a composition comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes and expresses PCV-2 ORF4, PCV-2 ORF13 or PCV-2 ORF4 and ORF13.
2. A method for reducing viral load of porcine circovirus-2 (PCV-2) in a pig comprising inducing an immunological or immunogenic response against PCV-2 in the pig comprising administering to the pig a composition comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes and expresses PCV-2 ORF13.
3. The method of claim 1 or claim 2 , wherein the composition additionally comprises at least one immunogen from at least one additional pig pathogen or a vector expressing such an immunogen.
4. The method of claim 3 wherein the composition additionally includes at least one immunogen from at least one additional pig pathogen.
5. The method of claim 3 wherein the at least one additional pig pathogen is selected from the group consisting of PRRS, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Escherichia coli , atrophic rhinitis, pseudorabies, hog cholera, swine influenza, encephalomyocarditis virus, and PPV.
6. The method of claim 5 , wherein the at least one additional pig pathogen is PPV.
7. The method of claim 1 or claim 2 , wherein the vector comprises a DNA plasmid, an E. coli cell, a baculovirus, a pig herpes virus, Aujeszky's disease virus, a porcine adenovirus, or a poxvirus.
8. The method of claim 7 , wherein the vector is a DNA plasmid.
9. The method of claim 7 , wherein the vector is a canarypox virus.
10. The method of claim 1 , additionally comprising at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector expressing the immunogen can also be the vector expressing PCV-2 ORF4, or PCV-2 ORF13 or PCV-2 ORF 4 and ORF13.
11. The method of claim 10 wherein the at least one additional pig pathogen is selected from the group consisting of PRRS, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Escherichia coli , atrophic rhinitis, pseudorabies, hog cholera, swine influenza, encepaphalomyocarditis virus, and PPV.
12. The method of claim 1 or claim 2 , wherein the administering is prior to breeding.
13. The method of claim 1 or claim 2 , wherein the pig is a pregnant female pig.
14. The method of claim 1 , wherein the vector contains and expresses PCV-2 ORF4 and ORF13.
15. The method of claim 1 , wherein the vector contains and expresses PCV-2 ORF4.